Call for Submissions: The Clinical & Public Health Implications of Abortion Bans & Restrictions
The Supreme Court’s decision to overturn Roe v. Wade has major national public health repercussions. While abortion has long been a hot topic in the political arena, we believe it should be viewed through a clinical and public health lens, not via one’s political ideology. Cureus is calling for submissions that relate to or address the clinical and public health implications of abortion bans and restrictions. We hope this initiative will help raise awareness and prompt discussion about abortion, reproductive rights and maternal mortality. While the United Stated Supreme Court decision to overturn Roe v. Wade prompted this call for articles, we understand that abortion access and reproductive rights are a global topic affecting people all over the world. Editors will consider original articles, review articles, editorials, case reports, and “autobiographical case reports.” Please add the keyword “abortion” to your submission to be included in the email campaign and newsroom page. The deadline for submissions is October 31st, 2022. Example topics: Policy Surveillance for a Global Analysis of National Abortion Laws How Caring for Patients Could Change in a Post–Roe v. Wade US Experiences of Midwives and Nurses When Implementing Abortion Policies: A Systematic Integrative Review Navigating Loss of Abortion Services — A Large Academic Medical Center Prepares for the Overturn of Roe v. Wade Abortion: Access and Safety Worldwide
Jun 28, 2022
A Case of Idiopathic Cold Agglutinin Hemolytic Anemia Successfully Treated With Steroids
Read the full story from coldagglutininnews.com. A 71-year-old woman with primary cold agglutinin disease (CAD) was successfully treated with the glucocorticoid prednisone, a case study reported. Its scientists noted that primary CAD typically does not respond to glucocorticoids, but in particular instances like this case, it can. The study, “A Case of Idiopathic Cold Agglutinin Hemolytic Anemia Successfully Treated With Steroids,” was published in the journal Cureus. In CAD, autoantibodies known as cold agglutinins bind to red blood cells at low temperatures, causing them to clump together and die in a process called hemolysis. While in primary CAD the cause of the disease is unknown, secondary CAD is associated with an underlying illness, such as an infection, another autoimmune disorder, or some types of cancer.
Jun 10, 2022
Cureus Call for Submissions: Mental Health Awareness
May is Mental Health Awareness Month Each year millions of people all over the world face the reality of living with a mental illness. This May, in honor of Mental Health Awareness month, Cureus is calling for submissions that relate to or address mental health concerns. We hope this initiative will help raise awareness and prompt discussion about mental health, which is often stigmatized or ignored.1,2 Cureus will accept submissions from all specialties. Editors will consider original articles, review articles, case reports, and “autobiographical case reports.” Please add the keyword “Mental Health” to your submission to be included in the email campaign and newsroom page. The deadline for submissions is July 31st, 2022 Example topics include: Depression and Vitamin D: A Peculiar Relationship The Therapeutic Effects of Ketamine in Mental Health Disorders: A Narrative Review Video Conferencing Dysmorphia: Assessment of Pandemic-Related Body Dysmorphia and Implications for the Post-lockdown Era The Importance of Diagnosing Concomitant Delirium and Catatonia: A Case Report
May 04, 2022
Call for Submissions: Psychoactive Drug Therapy
Deadline Extension: June 30th, 2022 Cureus is calling for submissions related to psychoactive therapeutic drug treatments. Relevant original articles, case reports, review articles, and technical reports will be featured on a devoted Therapeutic Psychoactive Drug Treatments page and email campaign. Examples of psychoactive drugs include (but are not limited to) psilocybin, MDMA, LSD, DMT, and cannabinoids. Once thought to be a dangerous and taboo part of counterculture, psychoactive drugs are gaining mainstream acceptance in the medical community. Several states and cities in the United States and countries around the world are beginning to legalize or decriminalize psilocybin and other psychoactive drugs for therapeutic or medicinal purposes. (1) Respected institutions such as Johns Hopkins University, the University of California, and the Icahn School of Medicine have opened centers to study psychedelics from a clinical perspective. (2) Several studies suggest these drugs can be safely administered and may have benefits for people with clinical depression and other psychological diagnoses, such as PTSD and anxiety. (3) Add the keyword “Psychoactive Drug” to your submission to be included in the email campaign and newsroom page. The deadline for submissions is June 30th, 2022. Cureus will accept submissions from all specialties. Example topics include: How ecstasy and psilocybin are shaking up psychiatry Psychedelic-assisted psychotherapy: a paradigm shift Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders Neuroscience of psychoactive substance use and dependence Psychedelics in palliative care
May 03, 2022
Submit Your "Autobiographical Case Report"
Submit your "autobiographical case report." *Now accepting submissions indefinitely. Physicians bring a unique perspective to the understanding of any disease and are often poised to provide lifelong outcomes for chronic diseases and/or their treatments. Many doctors are sitting on a treasure trove of medical knowledge learned firsthand through life experience - insights that never get reported in big clinical studies. Countless potential patients and their physicians can benefit from your wisdom. It’s time to tell your story in a Cureus case report! Please add “Autobiographical Case Report” as a keyword in your submission. We understand you may not have images related to your case, but we strongly encourage you to include any images you do have. Take a look at this published example and submit your case report (all specialties accepted) for the opportunity to be featured on a devoted Autobiographical Case Report page!
May 03, 2022
Video Abstract Submissions
Submit a Video Abstract Summary Cureus is dedicated to helping authors promote their research within the medical community. Short videos describing your article and findings build buzz and spread awareness of your research. Submit a 30-second to two-minute “self-portait-style” video summary of your Cureus article and we’ll share your video with over 50,000 people across our Facebook, YouTube, Twitter, LinkedIn, and Instagram accounts. *You do not need your own social media accounts to participate. *Medical students should clearly state the name of the submitting author who oversaw the research. You can see examples of video abstract summaries here and here! Where to start? Record a short video (no more than two minutes) on your computer or phone that provides insight into your published Cureus article. What to include: Introduce yourself (your name and institution). You may have more than one author present in the video so feel free to include your co-authors. What was the conclusion of your research? Why is this topic of interest to the general public or the medical community? What will you do next? Will you expand on this research? Are you starting new research? What to be aware of: Please stay on topic and stick to the subject matter of the article. Make sure there is ample lighting. Find a quiet place to film, free of any background noise and distractions. We recommend adding subtitles to your video but this is not required. We suggest the website: https://www.veed.io/ You can email your video to [email protected] Please include any social media handles for you, your co-authors, and your institution so we can tag everyone properly. Don't forget to subscribe to our YouTube Channel!
Apr 25, 2022
Presentation Documenting Use of IRRAflow System Confirms Potential Improved Outcomes Compared to Traditional Drainage Solutions
Sponsored by IRRAS Presentation of Largest Dataset to Date Documenting Use of IRRAflow System Confirms Potential Improved Outcomes Compared to Traditional Drainage Solutions The neurosurgery team from the Rockefeller Neuroscience Institute at West Virginia University and WVU Medicine Ruby Memorial Hospital (WVUH), led by Dr. Nicholas Brandmeir, presented the clinical outcomes from the first 45 patients they treated with the new breakthrough technology, IRRAflow, a dynamic system that provides a therapeutic approach to treating intracranial bleeding. The data presented confirms the preliminary effectiveness of the IRRAflow system’s automated irrigation by showing a 0% occlusion rate during the entire course of treatment. On the other hand, clinical literature documents that traditional passive drainage solutions have catheter occlusion rates of up to 47%.1 Additionally, IRRAflow’s mechanism of action was also shown to more effectively remove collected blood after intracranial bleeding. The average treatment time with IRRAflow was 6.8 days, and only 13% of patients required the placement of a shunt after IRRAflow treatment. This percentage of shunt dependence with IRRAflow compares favorably to data from the CLEAR-III where 18% of patients required shunt placement after treatment with a passive ventricular drain. Click the image above to view the PDF and learn about how preliminary data confirms that IRRAflow might reduce rates of catheter occlusion, infections, symptomatic and radiographic vasospasm. 1. Fargen KM, Hoh BL, Neal D, O’Connor T, Rivera-Zengotita M, Murad GJ. The burden and risk factors of ventriculostomy occlusion in a high-volume cerebrovascular practice: results of an ongoing prospective database. Journal of Neurosurgery. 2015:1-8.
Mar 29, 2022
Drainage, Irrigation, and Fibrinolytic Therapy (DRIFT) for Adult Intraventricular Hemorrhage Using IRRAflow®
An article on drainage, irrigation, and fibrinolytic therapy (DRIFT) for adult intraventricular hemorrhage published in Cureus was picked up by Medical Device News Magazine Read the Cureus article here: Drainage, Irrigation, and Fibrinolytic Therapy (DRIFT) for Adult Intraventricular Hemorrhage Using IRRAflow® Self-Irrigating Catheter Article from Medical Device News Magazine *Thumbnail image from https://irras.com/
Mar 22, 2022
COVID-19 Infection Can Worsen CAD Symptoms, Report Highlights
COVID-19 can worsen symptoms of cold agglutinin disease (CAD), a recent case report highlights. The scientists stressed the need for further research to determine the best ways to care for people with new or worsening CAD that develops in the context of a COVID-19 infection. In this case, treatment with remdesivir and dexamethasone resulted in “significant improvement in the patient’s condition,” they wrote. Read the full article from Cold Agglutinin Disease News here.
Mar 14, 2022
Breast Cancer Awareness Submissions
We’d like to thank all of the authors who participated in our “Breast Cancer Awareness” call for submissions in honor of Breast Cancer Awareness Month. Breast cancer affects a multitude of specialties and millions of people all over the world and your work continues to power advancements in the fight against this deadly disease Click below to view the articles published on this topic, and stay on the lookout for new calls for article submissions on major clinical topics.
Feb 08, 2022
Autobiographical Case Report Submissions
We'd like to thank all of the authors who participated in our one-of-a-kind campaign soliciting autobiographical case reports. Physicians possess a treasure trove of medical knowledge and much of it is accessible only via this unique publication method as demonstrated by dozens of published firsthand accounts. We will continue to accept autobiographical case report submissions indefinitely due to your enthusiastic reception of this exciting new idea in case report publishing. Stay on the lookout for new calls for article submissions on major clinical topics and thank you once again for your support of Cureus!
Feb 07, 2022
See examples of past Social Boost performances
Authors who qualify and purchase Social Boost continue to see a major audience increase. *Visit your author dashboard to see if you qualify. The following article was published in February and boosted in May 2021, leading to over 4,000 additional reads, 56 tweets and one news article (with just a premium boost). And to top it off, the article was later cited in the Annals of Internal Medicine. This next article was boosted twice and eventually cited in the International Journal of Molecular Science. The spikes on the chart in December and May directly correlate with the two Social Boosts.
Jan 17, 2022